Not Every Biomarker Is a Mutation: What FRα Teaches Us About Precision Oncology

Article

Precision oncology has become deeply associated with genomic testing. We sequence tumors, identify mutations, map signaling pathways, and search for therapeutically actionable alterations. That approach has transformed cancer care. But it can also create a conceptual blind spot: not every actionable feature of a cancer is written as a mutation in its DNA. Folate receptor alpha, or FRα, in high-grade serous ovarian cancer provides an important example. FRα is a cell-surface protein encoded by the FOLR1 gene and is frequently highly expressed in ovarian cancer. Yet the clinically relevant question is generally not whether FOLR1 contains a pathogenic mutation. It is whether enough FRα protein is actually displayed on the surface of the tumor cells to make it therapeutically useful. That requires a different kind of precision diagnostic. Instead of sequencing DNA, FRα expression is evaluated using immunohistochemistry, allowing a pathologist to determine both the proportion of tumor cells expressing the receptor and the intensity of membrane staining. Why does this distinction matter? Because FRα can function as a molecular address. Mirvetuximab soravtansine is an antibody-drug conjugate designed to recognize FRα on the tumor-cell surface. After binding, the complex is internalized and delivers the cytotoxic payload DM4 into the cancer cell, disrupting microtubules. The receptor does not need to be the oncogenic engine driving the cancer for it to be therapeutically valuable. It simply needs to provide a sufficiently selective and abundant target through which therapy can be delivered. That represents a different paradigm from biomarkers such as BRCA1 and BRCA2. BRCA and homologous recombination deficiency identify an internal biological vulnerability: impaired DNA repair that can be therapeutically exploited. FRα identifies an external cellular phenotype: a protein displayed on the tumor surface that can be used to direct a therapeutic payload. Both are precision medicine. But they require different diagnostics to reveal them. And that distinction has implications well beyond ovarian cancer. The next generation of precision oncology will increasingly depend on integrating multiple layers of tumor biology: DNA sequence, genomic instability, RNA expression, protein abundance, cell-surface phenotype, immune context, and potentially spatial relationships within the tumor microenvironment. No single testing modality captures all of that information. The lesson from FRα is therefore larger than the biomarker itself. Comprehensive precision oncology should not simply ask, “What mutations does this tumor have?” It should ask: “What is different about this tumor that we can measure—and therapeutically exploit?” Sometimes the answer is encoded in the genome. Sometimes it is revealed by the damage the genome has accumulated. And sometimes, as with FRα, the actionable biology is displayed directly on the surface of the cancer cell. Animedix — translating precision medicine from scientific discovery to clinical understanding.